Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open‐label, 2:1 randomized, treat‐to‐target trial

AIMS: To assess the efficacy and safety of twice‐daily insulin degludec/insulin aspart (IDegAsp) versus biphasic insulin aspart 30 (BIAsp 30) twice daily, both ± metformin, in Chinese adults (N = 543) with type 2 diabetes (T2D) inadequately controlled on premixed/self‐mixed or basal insulin ± metfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Wenying, Ma, Jianhua, Hong, Tianpei, Liu, Ming, Miao, Heng, Peng, Yongde, Wang, Changjiang, Xu, Xiangjin, Yang, Tao, Nielsen, Anne M., Pan, Lili, Liu, Weihong, Zhao, Weigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617768/
https://www.ncbi.nlm.nih.gov/pubmed/30869183
http://dx.doi.org/10.1111/dom.13703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617768/
https://www.ncbi.nlm.nih.gov/pubmed/30869183
http://dx.doi.org/10.1111/dom.13703

Ejemplares similares